Percona and Chainguard aim to cut CVE patching and reduce overhead with secure-by-default images for open-source databases.

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...

Customer stories Events & webinars Ebooks & reports Business insights GitHub Skills ...

NGX Storage’s CEO and founder, Beyhan Çalışkan, outlines how a Turkish‑born storage vendor has grown into a multi‑continent ...